BHVN
|Biohaven Pharmaceutical Holding Co Ltd
NYSE
USD 16.20
-0.01|-0.06%
Current Price
USD 16.20
Change
USD -0.01 (-0.06%)
P/E Ratio
Dividend Yield
Market Cap
1.51B
Volume
1.08M
Open
USD 16.16
Previous Close
USD 16.21
52-Week High
USD 55.70
52-Week Low
USD 14.50
About Biohaven Pharmaceutical Holding Co Ltd
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 tha...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Vladimir Coric M.D.
Employees:256
Headquarters:New Haven, USA
Website:www.biohaven.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions